Market Intelligence, Clinical Progress, and High-Purity Reagents for Neuroblastoma and Small Cell Lung Cancer Therapeutics.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for GPC2 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | GPC2 ECD-Fc / Mutant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 Expressed (Native Glycosylation). |
View GPC2 Products |
| Gene Delivery | GPC2 Promise-ORF / Lentivirus Full-length ORF for stable cell lines. Ideal for cell-based assays preserving native conformation. |
View GPC2 Products |
| Benchmark Ab | Anti-GPC2 (Sequence of D3-GPC2) Recombinant positive control for binding and internalization assays. |
View GPC2 Products |
| Validator | GPC2 siRNA Set For knockdown verification and specificity controls in functional assays. |
View GPC2 Products |
| Related Target A | GPC3 High-homology family member. Crucial for cross-reactivity screening to prevent off-target toxicity. |
View GPC3 Products |
| Related Target B | ALK Frequently co-expressed or mutated in neuroblastoma. Key target for synergistic combination therapies. |
View ALK Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Subfamily Cross-Reactivity (GPC1-6) | Homolog panel proteins (GPC1, GPC3, GPC4, GPC5, GPC6) strictly verified by mass spectrometry and high purity (>95%). |
| ADC Internalization Validation | HEK293-expressed GPC2 with native glycosylation patterns, ensuring correct folding for physiological internalization assays. |
| Lack of Controls | Clinical Benchmark Antibodies (Biosimilars) included for assay standardization. |
| False Positives | Validated siRNA included for target-specific knockdown verification. |
Live GPC2 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for GPC2 therapeutics is intensifying, with major players shifting focus from traditional mAbs to CAR-T therapies and Antibody-Drug Conjugates (ADCs). As first-generation therapies reach the clinic, the next wave of R&D is targeting pediatric neuroblastoma and adult small cell lung cancer (SCLC) where GPC2 is highly overexpressed compared to normal adult tissues. Addressing target density requirements and avoiding cross-reactivity with other glypicans are the primary engineering bottlenecks.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| CAR-T / CAR-NK | National Cancer Institute (NCI), Stanford University | Neuroblastoma, Medulloblastoma | Cell-based cytotoxicity assays (GPC2 overexpressing stable cell line via Lentivirus) |
| ADC | Academic Institutes, Biotech Players | Small Cell Lung Cancer (SCLC), Neuroblastoma | Internalization Assay (Need high-purity, natively glycosylated ECD-Fc) |
| Bispecific / Multi-specific | Clinical-stage Biotechs | Solid Tumors | Selectivity Assay (Need GPC family recombinant proteins for counter-screening) |